NCT04645368

Study of Longidaze in the Prevention & Treatment of Pulmonary Fibrosis, Interstitial Lung Diseases Caused by COVID-19

Multicenter, Open-label Prospective Cohort Study of the Efficacy and Safety of the Inclusion of Longidaze in the Prevention and Treatment of Post-inflammatory Pulmonary Fibrosis and Interstitial Lung Diseases Caused by COVID-19.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 160 (actual)
• Sponsor: NPO Petrovax · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A study is being conducted to evaluate the efficacy and safety of Longidaze for the prevention and treatment of post-inflammatory pulmonary fibrosis and interstitial lung disease following COVID-19.

Detailed description

The aim of the study is to compare the outcomes associated with postinflammatory pulmonary fibrosis and interstitial lung disease among a cohort of adult patients after complicated pulmonary manifestations of COVID-19 in two groups: in a group of patients who were prescribed Longidaze® for treatment or prevention as part of routine clinical practice, and in the group of patients who underwent dynamic observation.

Conditions

• Fibroses, Pulmonary

Interventions

Type	Name	Description
DRUG	bovhyaluronidase azoxymer	3000 IU intramuscularly once every 5 days with a course of 15 injections

Timeline

• Start date: 2020-07-01
• Primary completion: 2022-04-20
• Completion: 2022-04-20
• First posted: 2020-11-27
• Last updated: 2024-04-23

Locations

15 sites across 1 country: Russia